fenofibrate has been researched along with Weight Gain in 17 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To test the hypothesis that limitations on fat oxidation underlie this propensity for diet-induced obesity, rats were treated with fenofibrate, which enhances fat oxidation mainly in liver by inducing expression of enzymes and proliferation of organelles involved in fatty acid oxidation." | 7.73 | Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats. ( Friedman, MI; Ji, H; Outterbridge, LV, 2005) |
| " Furthermore, Fenofibrate prevents one of the most undesirable effects of Rosiglitazone, namely increased adiposity and body weight gain." | 7.73 | Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice. ( Bross, A; Carmona, MC; Casteilla, L; Dacquet, C; Desbazeille, M; Louche, K; Nibbelink, M; Pénicaud, L; Prunet, B; Renard, P, 2005) |
| " To determine whether fenofibrate reduces body weight gain and adiposity in female sham-operated (Sham) and ovariectomized (OVX) C57BL/6J mice, the effects of fenofibrate on not only body weight, white adipose tissue (WAT) mass, and food intake, but also the expression of both leptin and PPARalpha target genes were measured." | 7.72 | Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. ( Choi, JH; Han, M; Jeong, S; Kim, BH; Kim, J; Kim, M; Lee, H; Nam, KH; Nicol, CJ; Oh, GT; Yoon, M, 2004) |
| "Fenofibrate prevented the increase in BP in 4-5 week old SHRSP, reduced BP in 25 week old SHRSP, but had no effect on BP in normotensive SD rats." | 5.31 | Fenofibrate lowers blood pressure in two genetic models of hypertension. ( Quest, DW; Shatara, RK; Wilson, TW, 2000) |
| "The present work was designed to investigate whether fenofibrate could ameliorate olanzapine deleterious effect on insulin resistance via its effect on fibroblast growth factor-21 (FGF-21)-adiponectin axis without affecting olanzapine antipsychotic effect in postweaning socially isolated reared female rats." | 4.02 | Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis. ( Ali, AA; El-Bakly, WM; El-Demerdash, E; El-Kilany, SS; Galal, A, 2021) |
| " In this study, we aimed to: a) evaluate hamster as a model for insulin resistance, hyperlipidemia and atherosclerosis; and b) investigate the effect of a PPAR-α activator, fenofibrate, in this model." | 3.76 | Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster. ( He, S; Srivastava, RA, 2010) |
| " These mice had an obese body, lipid metabolic disorder and insulin resistance and were treated orally with 100 mg/kg/day 3'-deoxyadenosine (DA), 15 mg/kg/day rosiglitazone and 150 mg/kg/day fenofibrate, respectively." | 3.76 | Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice. ( Liu, Q; Niu, YJ; Tao, RY; Tian, JY; Ye, F; Zhu, HB; Zhu, P, 2010) |
| " Rosiglitazone reduced fasting glucose and insulin but induced weight gain." | 3.75 | Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. ( Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA, 2009) |
| " To test the hypothesis that limitations on fat oxidation underlie this propensity for diet-induced obesity, rats were treated with fenofibrate, which enhances fat oxidation mainly in liver by inducing expression of enzymes and proliferation of organelles involved in fatty acid oxidation." | 3.73 | Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats. ( Friedman, MI; Ji, H; Outterbridge, LV, 2005) |
| "The effect of fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, on body weight gain and on reduction of adipose tissue pads has been ascribed to increased fat catabolism in liver mainly through the induction of target enzymes involved in hepatic lipid metabolism." | 3.73 | Effects of fenofibrate on lipid metabolism in adipose tissue of rats. ( Botion, LM; Ferreira, AV; Green, A; Parreira, GG, 2006) |
| " In a chronic-dosing study, equiefficacious antihyperglycemic doses of the PPAR gamma agonist pioglitazone and PPAR alpha/gamma dual activator ragaglitazar were administered to obesity-prone male rats." | 3.72 | Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. ( Jensen, PB; Larsen, LK; Larsen, PJ; Sørensen, RV; Vrang, N; Wassermann, K; Wulff, EM, 2003) |
| " To determine whether fenofibrate reduces body weight gain and adiposity in female sham-operated (Sham) and ovariectomized (OVX) C57BL/6J mice, the effects of fenofibrate on not only body weight, white adipose tissue (WAT) mass, and food intake, but also the expression of both leptin and PPARalpha target genes were measured." | 3.72 | Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. ( Choi, JH; Han, M; Jeong, S; Kim, BH; Kim, J; Kim, M; Lee, H; Nam, KH; Nicol, CJ; Oh, GT; Yoon, M, 2004) |
| "Inducing renal cytochrome P4504A (P4504A) activity with clofibrate prevents the development of hypertension in Dahl salt-sensitive (Dahl S) rats." | 3.70 | Effects of lipid-lowering agents in the Dahl salt-sensitive rat. ( Alonso-Galicia, M; Roman, RJ; Wilson, TW, 1998) |
| "Fenofibrate is an antilipemic agent that exerts its therapeutic effects through activation of peroxisome proliferator-activated receptor α (PPAR α)." | 1.37 | Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels. ( Chang, CJ; Chang, YS; Liou, SS; Liu, IM; Tzeng, TF, 2011) |
| "Fenofibrate prevented the increase in BP in 4-5 week old SHRSP, reduced BP in 25 week old SHRSP, but had no effect on BP in normotensive SD rats." | 1.31 | Fenofibrate lowers blood pressure in two genetic models of hypertension. ( Quest, DW; Shatara, RK; Wilson, TW, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Galal, A | 1 |
| El-Bakly, WM | 1 |
| El-Kilany, SS | 1 |
| Ali, AA | 1 |
| El-Demerdash, E | 1 |
| Alemán, MN | 1 |
| Sánchez, SS | 1 |
| Honoré, SM | 1 |
| Choi, JH | 2 |
| Kim, MK | 1 |
| Yeo, SH | 1 |
| Kim, S | 1 |
| Fernandes-Santos, C | 1 |
| Evangelista Carneiro, R | 1 |
| de Souza Mendonca, L | 1 |
| Barbosa Aguila, M | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Srivastava, RA | 2 |
| He, S | 1 |
| Niu, YJ | 1 |
| Tao, RY | 1 |
| Liu, Q | 1 |
| Tian, JY | 1 |
| Ye, F | 1 |
| Zhu, P | 1 |
| Zhu, HB | 1 |
| Chang, CJ | 1 |
| Tzeng, TF | 1 |
| Liou, SS | 1 |
| Chang, YS | 1 |
| Liu, IM | 1 |
| Larsen, PJ | 1 |
| Jensen, PB | 1 |
| Sørensen, RV | 1 |
| Larsen, LK | 1 |
| Vrang, N | 1 |
| Wulff, EM | 1 |
| Wassermann, K | 1 |
| Jeong, S | 1 |
| Han, M | 1 |
| Lee, H | 1 |
| Kim, M | 1 |
| Kim, J | 1 |
| Nicol, CJ | 1 |
| Kim, BH | 1 |
| Nam, KH | 1 |
| Oh, GT | 1 |
| Yoon, M | 1 |
| Ji, H | 1 |
| Outterbridge, LV | 1 |
| Friedman, MI | 1 |
| Carmona, MC | 1 |
| Louche, K | 1 |
| Nibbelink, M | 1 |
| Prunet, B | 1 |
| Bross, A | 1 |
| Desbazeille, M | 1 |
| Dacquet, C | 1 |
| Renard, P | 1 |
| Casteilla, L | 1 |
| Pénicaud, L | 1 |
| Jahagirdar, R | 1 |
| Azhar, S | 1 |
| Sharma, S | 1 |
| Bisgaier, CL | 1 |
| Zhao, X | 1 |
| Quigley, JE | 1 |
| Yuan, J | 1 |
| Wang, MH | 1 |
| Zhou, Y | 1 |
| Imig, JD | 1 |
| Ferreira, AV | 1 |
| Parreira, GG | 1 |
| Green, A | 1 |
| Botion, LM | 1 |
| Vickers, MH | 1 |
| Hofman, PL | 1 |
| Gluckman, PD | 1 |
| Lobie, PE | 1 |
| Cutfield, WS | 1 |
| Wilson, TW | 2 |
| Alonso-Galicia, M | 1 |
| Roman, RJ | 1 |
| Shatara, RK | 1 |
| Quest, DW | 1 |
17 other studies available for fenofibrate and Weight Gain
| Article | Year |
|---|---|
Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis.
Topics: Adiponectin; Adipose Tissue; Animals; Antipsychotic Agents; Female; Fenofibrate; Fibroblast Growth F | 2021 |
Daily Intake of Smallanthus sonchifolius (Yacon) Roots Reduces the Progression of Non-alcoholic Fatty Liver in Rats Fed a High Fructose Diet.
Topics: Actins; Animals; Asteraceae; Diet; Fenofibrate; Fructose; Inflammation; Insulin; Lipids; Liver; Non- | 2022 |
Short-term Cudrania tricuspidata fruit vinegar administration attenuates obesity in high-fat diet-fed mice by improving fat accumulation and metabolic parameters.
Topics: Acetic Acid; Animals; Biomarkers; Cell Line; Cell Survival; Diet, High-Fat; Disease Models, Animal; | 2020 |
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietar | 2009 |
Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster.
Topics: Animals; Aorta; Atherosclerosis; Cholesterol; Cricetinae; Dietary Fats; Fenofibrate; Hyperlipidemias | 2010 |
Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice.
Topics: Animals; Area Under Curve; Cordyceps; Deoxyadenosines; Dietary Fats; Disease Models, Animal; Fenofib | 2010 |
Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels.
Topics: Acyl-CoA Oxidase; Adipocytes; Administration, Oral; Animals; Cytochrome P-450 CYP4A; Diet, High-Fat; | 2011 |
Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis.
Topics: Adipose Tissue; Animals; Biomarkers; Blood Glucose; Eating; Energy Metabolism; Fenofibrate; Gene Exp | 2003 |
Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice.
Topics: Adipose Tissue; Animals; Body Composition; Body Weight; Dietary Fats; Eating; Fatty Acids; Female; F | 2004 |
Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats.
Topics: Acyl-CoA Oxidase; Animal Nutritional Physiological Phenomena; Animals; Body Composition; Carnitine O | 2005 |
Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.
Topics: Animals; Body Composition; Depression, Chemical; Drug Therapy, Combination; Fatty Acids; Fenofibrate | 2005 |
Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
Topics: Adiposity; Animals; Aorta; Coronary Artery Disease; Diet, Atherogenic; Energy Metabolism; Fenofibrat | 2006 |
PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats.
Topics: Animals; Arachidonic Acid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme System; Eicosanoids; End | 2006 |
Effects of fenofibrate on lipid metabolism in adipose tissue of rats.
Topics: Adipose Tissue; Adiposity; Animals; Blood Glucose; Eating; Fenofibrate; Lipid Metabolism; Lipids; Li | 2006 |
Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat.
Topics: Animals; Birth Weight; Blood Pressure; Bone Development; Fatty Acids, Nonesterified; Female; Fenofib | 2006 |
Effects of lipid-lowering agents in the Dahl salt-sensitive rat.
Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Sy | 1998 |
Fenofibrate lowers blood pressure in two genetic models of hypertension.
Topics: Animals; Blood Glucose; Blood Pressure; Fenofibrate; Hypertension; Hypolipidemic Agents; Male; Prote | 2000 |